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Abstract
The function of the oxytocin receptor system is strongly dependent on steroids as demonstrated by several physiological studies. One key
element of this dependence on steroids may be the interaction of cholesterol and the oxytocin receptor. In this study, we show that cholesterol
stabilizes the solubilized human oxytocin receptor against thermal inactivation and proteolytic degradation. In the absence of additional
cholesterol, the soluble receptor inactivates within minutes. Maximal stabilization of the oxytocin receptor requires a continuous supply with
cholesterol from a cholesterol-rich environment. A structure–activity analysis of various cholesterol analogues and their effect on the thermal
stability of the oxytocin receptor showed that the stabilizing function of cholesterol was highly specific. The structural requirements of a
potent stabilizing steroid are very similar to those necessary to support the high-affinity state of the receptor. Moreover, in the presence of
cholesterol, the oxytocin receptor is significantly more stable against alterations of pH value (pH 4–12). The results show that cholesterol
acts as a general stabilizer of the oxytocin receptor.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cholesterol is one of the most abundant membrane
constituents in eukaryotic cells. The integrity of structures
such as caveolae and detergent-insoluble glycosphingolipid-
enriched microdomains (termed ‘DIGs’ or ‘rafts’) is
strongly dependent on the presence of cholesterol. In the
last years, these structures are considered as essential
components of cellular signal transduction [1,2]. Beyond
its well-documented effects on the structure and physical
state of the phospholipid bilayer, cholesterol has been
reported to modulate the functional activity of many mem-
brane proteins including G protein coupled receptors
(GPCR) such as rhodopsin [3], the oxytocin receptor
[4,5], the galanin receptor [6], and the A-opioid receptor [7].
GPCRs mediate and specify the signal transduction of the
majority of hormones and neurotransmitters. These receptor
proteins share a common topology with seven a-helical
transmembrane domains [8,9]. Since large fractions of these
proteins are embedded in the lipid bilayer of the plasma
membrane, the structure of the lipid bilayer should have a
profound influence on the molecular properties of the hepta-
helical receptors. However, the influence of the lipid bilayer
on receptor function is poorly understood. In this context, the
oxytocin receptor, a prototypical member of this receptor
superfamily, is an especially interesting candidate since its
binding affinity for ligands (agonists and antagonists) is
strongly dependent on the cholesterol level of the plasma
membrane [4,5,10,11]. In cholesterol-depleted myometrial
membranes, the oxytocin receptor was found in a low-
affinity state for agonistic as well as for antagonistic ligands
[4]. Moreover, expression of the oxytocin receptor in insect
cells, which naturally have cholesterol-poor membranes,
resulted in low-affinity state receptors that could be con-
verted to high-affinity state by adding cholesterol either to
the membranes or to the cells [5]. Obviously, both affinity
states are convertible to each other and the differences in
affinity of both receptor states were remarkably high (100–
200-fold). Using subcellular fractionation techniques, we
previously found that oxytocin receptors residing in choles-
terol-rich compartments of the plasma membrane were
significantly more stable against thermal inactivation as
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compared with receptors residing in cholesterol-poor
domains [12]. This previous observation prompted us to
explore the stabilizing function of cholesterol in more detail.
2. Materials and methods
2.1. Materials
[Tyrosyl-2,6-3H]oxytocin (NET-858, 48.5 and 32 Ci/
mmol) was from NEN Du Pont de Nemours (Bad Homburg,
Germany). The cholesterol oxidase assay kit was purchased
from Roche Diagnostics (Mannheim, Germany). The anti-
GFP antibody was from BD Biosciences Clontech (Heidel-
berg, Germany). MhCD was from Aldrich and all other
chemicals were purchased from Sigma (Deisenhofen, Ger-
many).
2.2. Methods
2.2.1. Construction of the recombinant oxytocin receptor,
cell culture, and DNA transfections
The cDNA encoding the human oxytocin receptor (OTR)
was a generous gift from Dr. Tadashi Kimura, Japan. The
EGFP-tagged oxytocin receptor was constructed as described
[12]. HEK293 cells and HEKOTRGFP cells were cultured in
monolayers in complete Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with penicillin, streptomy-
cin, and 10% (v/v) fetal calf serum.
2.2.2. Membrane preparation and solubilization
Membranes from transfected HEK 293 cells were pre-
pared as previously described [13]. Briefly, transfected cells
were suspended in buffer A (5 mM Hepes, pH 7.4, 1 mM
EDTA) and homogenized. The homogenate was first cen-
trifuged at 1000g for 10 min. The supernatant was
recentrifuged at 40,000g for 20 min. The pellet was
resuspended and rehomogenized in buffer B (20 mM Hepes,
pH 7.4, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), 0.1 mg/ml bacitracin, 0.1 mg/ml soybean
trypsin inhibitor, 5 Ag/ml antipain, 5 Ag/ml leupeptin and 1
Ag/ml pepstatin) and was then recentrifuged. The membrane
pellet was resuspended in buffer B at a protein concentration
of 2–10 mg/ml. Protein content was quantified by the
Bradford method using bovine serum albumin as a standard
[14].
Membranes (8 mg/ml of protein) from HEKOTRGFP
cells were incubated in solubilization buffer (10 mM
Chapso, 20 mM Hepes, pH 7.4, 300 mM NaCl, 5 mM
MgCl2) for 60 min at 4 jC. The homogenate was centrifuged
for 40 min at 165,000g (Ti60, Beckman), and the resulting
supernatant (soluble extract) was used immediately.
2.2.3. Receptor binding assays
To measure the ligand binding activity, membranes (2–
10 Ag) were incubated with [3H]oxytocin (5 nM) in a total
volume of 100 Al binding buffer (20 mM Hepes, pH 7.4, 5
mM MgCl2) for 30 min at 30 jC. For further character-
ization of the oxytocin binding sites, the membrane fractions
were incubated with 5 nM [3H]oxytocin in a volume of 100
Al binding buffer to which increasing concentrations of
unlabeled oxytocin were added. Some experiments required
longer incubation times at 37 jC (e.g. thermal stability
analysis). A cocktail of protease inhibitors (see components
of buffer B) was added to these assays. The bound radio-
ligand was separated by centrifugation (for 5 min at
21,000g).
The solubilized proteins (20 Al) were diluted (1:5) with
binding buffer (including 0.3 mM cholesterol-MhCD) to a
final concentration of 2 mM Chapso. Aliquots of the diluted
soluble extracts were incubated with 10 nM [3H]oxytocin in
a total volume of 100 Al for 30 min at 30 jC. The binding
reaction was stopped by addition of ice-cold binding buffer
(10 mM Tris, pH 7.4, 5 mM MgCl2) and bound ligand was
separated from free ligand by rapid filtration over Whatman
GF/F filters presoaked with 0.3% poly(ethylenimine). Fil-
ters were incubated with 10 ml scintillation cocktail (Filter-
Count, Packard) and were counted.
Nonspecific binding was determined in the presence of a
700–1000-fold excess of unlabeled oxytocin. All assays
were carried out in triplicate. Data analysis of the binding
studies was performed using the EBDA-LIGAND program.
Graphical output was performed by Sigmaplot version 5.0
(Jandel Scientific).
2.2.4. Immunoblots
Proteins were chloroform–methanol precipitated [15]
and were separated on 10% or 12% SDS-polyacrylamide
gels (SDS-PAGE). The separated proteins were transferred
to nitrocellulose filters, and were incubated for 1 h with
blocking solution (TBS with 5% nonfat dried milk). The
blots were incubated for 1 h with primary antibody (anti-
FLAG M2, 1:200 or anti-GFP, 1:500, each in blocking
solution) and for 30 min with secondary antibodies. The
blots were developed with the ECL-Plus system (Amersham
Biosciences, Freiburg, Germany).
2.2.5. Analytical methods
Cholesterol was assayed spectrophotometrically using a
Diagnostic kit (Roche Diagnostics) performed in a micro-
scale dimension. Protein was determined by the Bradford
assay using bovine serum albumin as a standard (Bio-Rad
Laboratories, Muenchen, Germany).
2.2.6. Lipid extraction
The samples were extracted with chloroform–methanol
according to the method of Bligh and Dyer [16], with slight
modifications. Briefly, 200 Al of membranes (10 Ag–1 mg
protein) and 0.75 ml chloroform–methanol (1:2, v/v) were
vigorously mixed for 10 min at 30 jC in a thermomixer and
centrifuged for 10 min at 21,000g. The supernatant was
mixed with 250 Al chloroform and 250 Al water and was
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centrifuged for 30 min at 21,000g. The bottom lipid phase
was evaporated under an N2 atmosphere and was dissolved
in isopropanol.
2.2.7. Preparation of steroid–cyclodextrin inclusion com-
plexes and alteration of the cholesterol content
For preparation of the steroid–MhCD inclusion com-
plexes, the steroids (final concentration 3 mM) were added
to an aqueous solution of MhCD (40 mg/ml) in a 2-ml tube.
The mixture was overlaid with N2, and was continuously
vortexed under light protection for 24 h at 30 jC in a
thermomixer. The solution was filtered through a millipore
filter (0.22 Am) prior to use.
Membranes were depleted of cholesterol as previously
described [11]. Briefly, membranes (4.2 mg/ml) were incu-
bated with MhCD (final concentration 30 mM) for various
times at 30 jC. Following a 30-min incubation with 30 mM
MhCD, about 80% of the initial cholesterol in membranes
has been removed. The membranes were washed twice and
were resuspended in assay buffer. To enrich the membranes
with cholesterol, the membranes were incubated with cho-
lesterol–MhCD (final concentration 0.3 mM of cholesterol
in complex) for various times.
2.2.8. Efficiency of steroids to restore the high-affinity state
of the oxytocin receptor
We measured the capability of steroids to restore the
high-affinity [3H]oxytocin binding of the membrane-embed-
ded oxytocin receptor. Membranes from HEKOTRGFP
cells were depleted of cholesterol (as described above under
Section 2.2.7 and in detail in Ref. [11]). The cholesterol-
depleted membranes (1.2 mg of protein in a volume of 285
Al) and the steroid–MhCD complexes (114 Al each con-
taining 3 mM of steroid) were mixed and incubated for 30
min at 30 jC under continuous stirring (see Section 2.2.7).
The membranes were washed once with assay buffer to
remove all of the steroids that were not incorporated into the
membranes. The washed pellet was resuspended in 300 Al
of assay buffer. A small aliquot of the membranes (50 Al)
was used for [3H]oxytocin binding as described (see Section
2.2.3). From the remainder (1 mg of protein) of the
membranes, the lipids were extracted [16] in order to check
for the incorporation of the steroids as described [11].
2.2.9. Influence of cholesterol on the stability of the oxytocin
receptor
In a series of experiments, we measured the stability of
the solubilized oxytocin receptor with respect to its resist-
ance to thermal inactivation and alterations of pH level in
dependence on cholesterol.
To examine the influence of cholesterol on the stability of
the receptor, the membranes were solubilized either in the
absence or presence of cholesterol–MhCD (0.3 mM in
solubilization buffer). Each of the soluble fractions were
split into two aliquots: one aliquot was supplied with addi-
tional cholesterol–MhCD (0.3 mM), the other was supplied
with buffer. Thereafter, the soluble extracts were incubated
for various times (0–60 min) at 30 jC. As a control, one
aliquot was incubated for 60 min at 4 jC. Then, all the
samples were adjusted to the same cholesterol concentra-
tions (0.3 mM) either by dilution or by adding cholesterol–
MhCD from a 3 mM stock solution to the soluble extracts.
The radioligand binding assay was performed as described
above.
To examine the stability of the receptor under conditions
of varying pH, membranes from HEKOTGFP cells were
centrifuged and were resuspended in buffer containing 20
mM amounts of the appropriate buffer, spanning the range
from pH 2 to pH 12, either in the absence or presence of
cholesterol–MhCD (0.3 mM final concentration). After 20
min of incubation at the different pH ranges, the membrane
fractions were neutralized by centrifugation and subsequent
washing and resuspension in binding buffer (20 mM Hepes,
pH 7.4, 5 mM MgCl2). Then, the radioligand binding assay
was performed as described above.
2.2.10. The influence of cholesterol on the proteolytic
degradation of the oxytocin receptor
We analyzed whether cholesterol is able to protect the
oxytocin receptor from proteolytic degradation using two
approaches: (i) membranes from HEKOTRGFP cells were
incubated in assay buffer at 30 jC for increasing times (0
min, 30 min, 4 h) either in the absence or presence of 0.3
mM cholesterol–MhCD. In these experiments, protease
inhibitors were not employed in order to allow the degra-
dation of the receptor by the activity of proteases endoge-
nously present in the membrane preparation. (ii) Membranes
or solubilized extracts from HEKOTRGFP cells were incu-
bated at 37 jC for various times (0–15 min) with porcine
trypsin (3 mg/ml) either in the absence or presence of added
cholesterol–MhCD (0.3 mM).
The samples were precipitated by chloroform–methanol
[15] and were processed for SDS-PAGE and subsequent
immunoblot. For detection of the receptor protein, an anti-
FLAG M2 or an anti-GFP antibody was used.
3. Results
3.1. Expression of the human oxytocin receptor in HEK293
cells
The human oxytocin receptor was tagged with the FLAG
epitope and EGFP, which allowed us to perform in vivo
analysis and immunodetection of the receptor. The EGFP/
FLAG-tagged human oxytocin receptor was stably
expressed in HEK293 fibroblasts. We have previously
demonstrated that the C-terminal tagging of the oxytocin
receptor with EGFP/FLAG neither changed the ligand bind-
ing and signal transduction characteristics of the receptor
nor did it alter the receptors’ distribution profile [12]. As
shown in Fig. 1A, EGFP-tagged oxytocin receptors were
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correctly localized at the plasma membrane of the cells.
Following administration of oxytocin, the receptors inter-
nalized within a few minutes (Fig. 1B). This agonist-
mediated internalization is a typical property of GPCRs
and contributes to the offset of signal transduction.
3.2. Thermal stability of the oxytocin receptor in depend-
ence on cholesterol
A protocol was designed to analyze the stabilizing effect
of cholesterol during and/or after solubilization. The only
detergents that allow a functional solubilization of oxytocin
receptors are Chaps or its derivative Chapso [17]. Our
previous work showed that solubilization with Chapso led
to a depletion of cholesterol [4]. Therefore, we measured the
cholesterol content in membranes from HEKOTRGFP cells
and in the corresponding Chapso extracts. The cholesterol
content in the membranes (26.5F2.6 Ag/mg protein) was
observed to be about 1.6-fold higher than the cholesterol
content in the corresponding Chapso extract (16.6F2.1 Ag/
mg protein).
Immediately after the oxytocin receptors have been
solubilized by these detergents on ice, the high-affinity
oxytocin binding starts to decrease when the receptor was
subjected to an increased temperature. This is illustrated in
Fig. 2a. In the absence of any additional cholesterol (indi-
cated as ‘Chol/’, i.e. employed neither before nor after
solubilization), the high-affinity ligand binding of the solu-
bilized oxytocin receptor substantially decreased within
5 min of incubation at 30 jC. The addition of cholesterol
markedly attenuated this inactivation process. The thermal
inactivation of the receptor activity was lowest when choles-
terol was added before and after solubilization (‘Chol+/+’).
Even under this experimental condition, about half of the
initial ligand binding activity of the receptor was lost after
an incubation period of 60 min (termination of the solubi-
lization process=time 0). Interestingly, the stability of the
receptor was higher when cholesterol was added just after
the termination of the solubilization process (‘Chol/+’) as
compared with the pretreatment of the solubilizing extract
with cholesterol (‘Chol+/’). In each case, the highest
decrease in ligand binding activity of the oxytocin receptor
occurred within the first 10 min of incubation at 30 jC.
Thus, cholesterol is necessary to stabilize the soluble oxy-
tocin receptor in a high-affinity state under each condition.
We also performed experiments at temperatures above 40
jC. However, at higher temperatures, the receptor inactiva-
tion occurred so fast that the inactivation kinetics were
difficult to obtain.
Next, we analyzed whether this stabilization process is
cholesterol-specific. For that purpose, a variety of choles-
terol analogues were tested for their capability to stabilize
soluble oxytocin receptors. Prior to application, the various
cholesterol analogues have been incorporated into methyl-
h-cyclodextrin. As shown in Table 1 (‘soluble extracts’),
certain ‘nonfunctional’ steroids revealed an [3H]oxytocin
binding that was lower than the ‘buffer control’ (13.0%)
but higher than the ‘MhCD control’ (3.3%). Most prob-
ably, during the incubation of the extracts (30 min) with
the steroid–MhCD complexes, the steroid content of the
inclusion complexes progressively diminishes according to
the equilibrium of steroids between donor and acceptor. So
the initial donor steroid–MhCD can also function as a
cholesterol acceptor. This could lead to a further attenu-
ation of the ligand binding to the receptors if a completely
inefficient steroid exchanges for cholesterol. The process of
cholesterol depletion is reflected by the ‘MhCD value’,
which was significantly lower than the ‘buffer control’.
Therefore, any binding higher than the ‘buffer control’
indicates a functional steroid. Steroids with a similar high
efficiency as cholesterol were cholesterol-5a-6a-epoxide
and 19-hydroxycholesterol. All of the other steroids were
either significantly less potent to stabilize the oxytocin
Fig. 1. Expression of the GFP-tagged oxytocin receptor in HEK 293 cells.
HEK cells were stably transfected with the human oxytocin receptor-GFP
DNA, grown onto poly-D-lysin coated coverslips and mounted in an
imaging chamber with temperature control (37 jC). Following stimulation
of the HEKOTRGFP cells with oxytocin (100 nM), the GFP-tagged
oxytocin receptor localized in the plasma membrane (A) undergoes
internalization (B). The images were captured by a CCD camera (excitation
at 488 nm, emission at 520F20 nm).
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receptor (h-sitosterol > 5-cholesten-3h-ol-7-one>dihydro-
cholesterol=22-ketocholesterol>5a-cholestan-3h-ol-7-
one>stigmastanol>coprostanol=stigmasterol) or were com-
pletely inactive such as 4-cholestene-3-on, 5a-cholestane,
25-hydroxycholesterol, lanosterol or progesterone.
We addressed the question whether this steroid specific-
ity is similar to the steroid specificity, which underlies the
high-affinity state of the membrane-embedded oxytocin
receptor. Using MhCD as cholesterol acceptor, membranes
from HEKOTRGFP cells were depleted of cholesterol.
About 80% of the initial cholesterol content (f26 Ag/mg
protein) in the membranes was removed and, concomitantly,
oxytocin receptors were converted from their high-affinity
state (Kdf1 nM) to low-affinity state (Kdf100 nM) as
previously described [4,5,11]. The cholesterol-depleted
membranes were then incubated with various steroid–
MhCD complexes and the capability of each of the steroids
to restore the high-affinity [3H]oxytocin binding was meas-
ured (Table 1, ‘membranes’). We evaluated only steroids
with high incorporation rates, corresponding to a steroid
content of 80–120% of the initial steroid, i.e. cholesterol
(100% is equal to 26.5 Ag/mg protein) (for further details,
Table 1
Efficiency of various steroids to stabilize the ligand binding function of the
oxytocin receptor
Steroid [3H]oxytocin binding in
Soluble extractsa Membranesb
dpm Percentage of
maximum
Percentage of
maximum
Cholesterol 5418F207 100.0F3.8 100.0F2.9
Cholesterol-5a-
6a-epoxide
5672F176 104.7F3.2 92.3F3.7
19-Hydroxycholesterol 5320F182 98.2F3.4 70.3F3.4
h-Sitosterol 4753F256 87.7F4.7 91.7F1.9
5-Cholesten-3h-
ol-7-one
4441F225 82.0F4.2 43.1F4.7
Dihydrocholesterol 4222F134 77.9F2.5 86.1F4.3
22-Ketocholesterol 4009F211 74.0F3.9 76.1F1.6
5a-Cholestan-3h-
ol-7-one
3174F129 58.6F2.4 65.1F3.4
Stigmastanol 2433F201 44.9F3.7 52.7F3.2
Coprostanol 1698F190 31.3F3.5 57.2F2.9
Stigmasterol 1763F172 32.5F3.2 56.6F3.2
Lanosterol 820F101 15.1F1.9 7.4F1.0
Progesterone 714F94 13.1F1.7 11.2F2.8
25-Hydroxycholesterol 558F87 10.3F1.6 13.2F1.5
5a-Cholestan 444F103 8.2F1.9 10.0F2.0
4-Cholesten-3-one 298F76 5.5F1.4 6.0F0.9
Buffer control 705F92 13.0F1.6 11.8F2.3
MhCD control 178F61 3.3F1.1 4.2F1.5
The values are meansFS.D. of triplicate determinations from a representa-
tive experiment (n=3).
a Membranes (8 mg/ml) from HEKOTRGFP cells were solubilized
with Chapso. The solubilized proteins (20 Al) were diluted (1:5) with
binding buffer (including 0.3 mM steroid–MhCD complexes) to a final
concentration of 2 mM Chapso. Aliquots of the diluted soluble extracts
were incubated with 10 nM [3H]oxytocin in a total volume of 100 Al for 30
min at 30 jC.
b Membranes (8 mg/ml) from HEKOTRGFP cells were depleted of
cholesterol as described in Section 2. Cholesterol-depleted membranes were
incubated with the indicated steroid–MßCD complexes (each 0.3 mM of
steroid) for 30 min at 30 jC. After washing off the donor complex, the
membranes were analyzed for high-affinity ligand binding using 5 nM
[3H]oxytocin.
Fig. 2. Thermal stability of the oxytocin receptor in dependence on
cholesterol (a) and cholesterol analogues (b). (a) Membranes (8 mg/ml)
from HEKOTRGFP cells were solubilized either in the absence (‘Chol/’)
or presence (‘Chol+/’) of cholesterol –MhCD (0.3 mM in solubilization
buffer). Each of the soluble fractions were split into two aliquots: one
aliquot was supplied with additional cholesterol–MhCD (0.3 mM) (n,
‘Chol/+’ or ., ‘Chol+/+’) whereas the other was supplied with buffer
(o,‘Chol/’ or 5, ‘Chol+/’). Thereafter, the soluble extracts were
incubated for the indicated times (0–60 min) at 30 jC. As a control, one
aliquot was incubated for 60 min at 4 jC. Then, all the samples were
adjusted to the same cholesterol concentrations (0.3 mM) either by dilution
or by adding cholesterol –MhCD from a 3 mM stock solution to the soluble
extracts. The oxytocin binding activity was determined using 10 nM of
[3H]oxytocin. The data represent the remaining binding activity in percent
of control binding at time t=0. The data are given as meansFS.D. of three
measurements in a representative experiment (n=3). (b) The efficiency of
steroids as stabilizers of the soluble oxytocin receptor (data from Table 1,
‘soluble extracts’) is correlated with the efficiency of these steroids to
restore the high-affinity state of the membrane-embedded oxytocin receptor
(Table 1, ‘membranes’). The data represent meansFS.D. of three
measurements in a representative experiment (n=3): dashed line, regression
line; dotted line, confidence interval at 99% (r2=0.8765).
G. Gimpl, F. Fahrenholz / Biochimica et Biophysica Acta 1564 (2002) 384–392388
see Ref. [11]). A correlation analysis was performed
between two data sets: the ‘efficiency of steroids as stabil-
izers of the soluble OT receptor’ (Table 1, ‘soluble extracts’)
versus the ‘efficiency of the same steroids to restore the
high-affinity state of the membrane-embedded oxytocin
receptor’ (Table 1, ‘membranes’). As shown in Fig. 2b, a
high degree of correlation was found between these sets of
data. From a total of 16 steroids that we have tested, 13
steroids were within the 99% confidence interval (Fig. 2b,
dotted line). This suggests that the same steroids that
support the high-affinity state of the oxytocin receptor most
likely also act as stabilizers of the soluble receptor.
3.3. The influence of cholesterol on the proteolytic
degradation of the oxytocin receptor
We now asked whether cholesterol could protect the
oxytocin receptor from proteolytic attacks. In the first series
of experiments, we analyzed the activity of proteases endo-
genously present in the plasma membranes of HEKOTRGFP
cells. For that purpose, membranes of HEKOTRGFP cells
were treated in the absence of any protease inhibitors at 30
jC for various times (0 min, 30 min, 4 h) either in the
absence or presence of added cholesterol. Using the anti-
FLAG M2 antibody, the receptor was detected on immuno-
blots by two specific bands, one at f90–105-kDa and a
slower migrating band at Mrf75,000 (Fig. 3). The band
representing the higher molecular mass is expected if one
calculates the size of the oxytocin receptor-EGFP/FLAG
fusion protein including three potential N-glycosylation sites
Fig. 3. Immunoblot analysis of the digestion of the oxytocin receptor by
endogenous proteases present in membranes of HEKOTRGFP cells. In the
absence of any protease inhibitors, membranes (0.1 mg) of HEKOTRGFP
cells were incubated at 30 jC for various times (0 min, 30 min, 4 h) in the
absence (lanes 1, 3, 5) or presence (lanes 2, 4, 6) of 0.3 mM cholesterol –
MhCD. At the indicated time, the membranes were processed for SDS-
PAGE (reducing conditions) and subsequent immunoblot. For specific
receptor detection, the anti-FLAG antibody M2 was used. The sharp band
at f75 kDa corresponds to the deglycosylated receptor.
Fig. 4. Immunoblot analysis of the trypsinolytic degradation process of the
oxytocin receptor in membranes of HEKOTRGFP cells. Membranes (0.1
mg) from HEKOTRGFP cells were incubated at 37 jC for 5 min (lanes 1
and 2) or 15 min (lanes 3 and 4) with porcine trypsin either in the absence
(lanes 2 and 4) or presence (lanes 1 and 3) of 0.3 mM cholesterol–MhCD.
At the indicated time, the membranes were processed for SDS-PAGE
(reducing conditions) and subsequent immunoblot. For specific receptor
detection, an anti-GFP antibody was used.
Fig. 5. Immunoblot analysis of the trypsinolytic degradation process of the
soluble oxytocin receptor from HEKOTRGFP cells. The oxytocin receptor
has been solubilized from membranes of HEKOTRGFP cells. The soluble
extracts were incubated at 37 jC for various times (0, 5 and 10 min) with
trypsin either in the absence (lanes 2, 4, 6) or presence (lanes 3, 5, 7) of 0.3
mM cholesterol –MhCD. At the indicated time, the soluble extracts were
processed for SDS-PAGE (reducing conditions) and subsequent immuno-
blot. For specific receptor detection, an anti-GFP antibody was used.
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whereas the Mr f75,000 polypeptide most likely corre-
sponds to the deglycosylated receptor form. As shown in Fig.
3, incubation at 30 jC led to a decreased intensity of both the
f90–105-kDa and the f75,000 polypeptide bands. The
deglycosylated receptor form appeared to be somewhat more
prone to digestion by endogenous proteases. Clearly, addi-
tional cholesterol prevented or at least slowed the process of
proteolytic degradation (Fig. 3). The observation that deg-
radation products of lower molecular sizes could not be
detected by the anti-FLAG M2 antibody suggests a prefer-
ential degradation of the N-terminal part of the receptor
where the FLAG epitope is localized.
Cholesterol did not only protect the oxytocin receptor
from proteolytic degradation by proteases that reside endo-
genously in the membranes but it also protects the receptor
from digestion by trypsin (Figs. 4 and 5). In these series of
experiments, an anti-GFP antibody was used for immuno-
detection of the oxytocin receptor. A limited digestion with
trypsin resulted in a partial degradation of the oxytocin
receptor into two major products of f48 and f38 kDa
polypeptides (Fig. 4). In membranes preincubated with
additional cholesterol (Fig. 4, lanes 1 and 3), the trypsin-
induced degradation of the 90–105 kDa band was signifi-
cantly lower than that in membranes without additional
cholesterol (Fig. 4, lanes 2 and 4). Similar results were
obtained in experiments with the soluble oxytocin receptor
(Fig. 5). However, in soluble extracts, the stabilizing effect
of cholesterol was relatively small. Apparently, the soluble
oxytocin receptor is more easily digested by trypsin as
compared with the membrane-embedded receptor (compare
Fig. 4, lane 1 with Fig. 5, lane 3; each after 5-min pretreat-
ment with trypsin). A short incubation with trypsin in the
absence of added cholesterol led to a complete digestion of
the fully glycosylated soluble receptor (Fig. 5, lane 3).
Possibly, the detergent stimulates the activity of trypsin or,
more likely, the solubilized receptor is better accessible to
the enzyme. Incubation with trypsin for different times (0, 5
and 10 min), resulted in a degradation of the fully glycosy-
lated oxytocin receptor form into a f40 kDa band. In
solubilized fractions pretreated with additional cholesterol,
slightly more of the fully glycosylated receptor is observed
as compared to untreated soluble extracts. Moreover, it
appears that in the presence of additional cholesterol, the
oxytocin receptor including all of its proteolytic degradation
products are protected from further (10 min) cleavage by
trypsin (Fig. 5, lanes 5 versus 6). The corresponding
proteolytic degradation patterns for the oxytocin receptor
were not further characterized since this was not the goal of
this study.
3.4. Stabilization of the membrane-embedded oxytocin
receptor under conditions of varying pH in dependence on
cholesterol
Finally, we examined the effect of cholesterol on the pH
range over which the oxytocin receptor remains stable as
determined by its high-affinity binding to [3H]oxytocin. In
untreated membranes (f25 Ag cholesterol/mg protein), the
oxytocin receptor still revealed a substantial amount of high-
affinity ligand binding after it has been subjected for 20 min
to different pH values within the range from 4 to 10 (Fig. 6,
open circles). When cholesterol was added (Fig. 6, filled
circles), the ligand binding of the oxytocin receptor was
significantly higher at each of the pH values tested as
compared with the ligand binding in the absence of addi-
tional cholesterol. In each case, maximum [3H]oxytocin
binding was observed following incubation of the mem-
branes at pH values between 7 and 9. We also measured
maximum ligand binding in membranes incubated at pH 10
in the presence of added cholesterol. Cholesterol-depleted
membranes (f6 Ag cholesterol/mg protein) revealed very
low high-affinity [3H]oxytocin binding, even at pH 7 and
pH 9 (Fig. 6, open squares).
4. Discussion
In this study, we show that cholesterol stabilizes the
solubilized oxytocin receptor against thermal inactivation
and proteolytic degradation. While the membrane-embed-
ded receptor represents the physiological relevant form, the
solubilized state of the receptor was analyzed since thereby
effects are eliminated that may be caused by properties of
the lipid bilayer such as membrane fluidity, thickness or
curvature. Clearly, employment of Chapso led to a depletion
of cholesterol as showed here (1.6-fold) and in our previous
Fig. 6. Stability of the membrane-embedded oxytocin receptor under
conditions of varying pH in dependence on cholesterol. Untreated (.,o) or
cholesterol-depleted (5) membranes (each 100 Ag per assay) from
HEKOTRGFP cells were subjected for 20 min to different pH values in
the presence (.) or absence (o,5) of cholesterol–MhCD (0.3 mM). For
that purpose, the membrane fractions were centrifuged and were
resuspended in buffer containing 20 mM amounts of the appropriate
buffer, spanning the range from pH 2 to pH 12. After 20-min incubation in
the appropriate buffer, the membranes were neutralized as described in
Section 2. Then, the [3H]oxytocin oxytocin binding activity was determined
using 10 nM of [3H]oxytocin. The data represent the binding activity
(meansFS.D.; n=3) expressed in percent of maximal radioligand binding.
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work [4]. Using uterine membrane fractions solubilized with
Chapso, we measured a cholesterol to phospholipid molar
ratio (C/P=0.43) that was 1.5-fold lower than that in the
native membrane (C/P=0.65) [4]. These data are in agree-
ment with studies from Banerjee et al. [18] who reported a
1.7-fold lower C/P ratio in membranes solubilized with
Chaps. Interestingly, digitonin, a detergent leading to com-
plete depletion of cholesterol in the solubilized fraction due
to the formation of insoluble 1:1 complexes with choles-
terol, was completely unable to solubilize any functional
oxytocin receptor [17].
In the absence of additional cholesterol, the soluble
receptor inactivates rapidly within minutes. For maximal
stabilization of the oxytocin receptor, a continuous supply
from a cholesterol-rich environment appears to be required.
The structure–activity analysis showed that the stabilizing
function for the oxytocin receptor was highly cholesterol-
specific. Overall, the structural requirements of a potent
steroid are very similar to those necessary to support the
high-affinity state of the membrane-bound oxytocin recep-
tor [11]. Thus, we hypothesize that one or more cholesterol
molecule(s) may bind to the oxytocin receptor and, thereby,
a conformational change of the receptor is induced. In its
cholesterol-bound state, the oxytocin receptor has an about
100-fold higher affinity for agonists and antagonists [4,5]
and is, as shown here, more resistant to thermal inactiva-
tion and proteolytic digestion. A stabilizing function of
cholesterol has also been described for other proteins. So,
inclusion of cholesterol to lipid vesicles increased the a-
bungarotoxin binding site stability of the Torpedo californ-
ica acetylcholine receptor against thermal inactivation [19].
Furthermore, in studies with rhodopsin, the incorporation
of cholesterol resulted in a significant increase in the
denaturation temperature under various experimental con-
ditions [3,20,21]. There is indeed evidence that the GPCR
rhodopsin exists in distinguishable receptor states, which
differed with respect to structural stability [22]. On the
other hand, cholesterol cannot be regarded as a general
stabilizer of receptor function. So, changes of the choles-
terol content in ovarian membranes had essentially no
effect on the thermal stability of the LH/hCG receptor [23].
Recent reports on the behavior of constitutively active
GPCRs suggest a connection between protein stability and
the signaling function of receptor proteins [24,25]. The
structural instability of a constitutively active h2 adrenergic
receptor has been demonstrated by an increased rate of
denaturation of the purified receptor at 37 jC as compared
with the wild-type receptor. It was proposed that the
unstable receptor mutant may readily undergo transitions
between the inactive and the active state, which makes it
more susceptible to denaturation [24]. In the presence of
ligand, an increased expression of the constitutively active
receptor has been observed, presumably by stabilization of
the inherently unstable receptor molecule [25]. In case of the
oxytocin receptor, cholesterol constrains the receptor in its
high-affinity conformation where it is less prone to thermal
inactivation and more resistant to proteolytic degradation. A
lower degree of conformational flexibility in a cholesterol-
rich microenvironment might stabilize the oxytocin receptor
in a low-energy state, which could help maintain a low basal
receptor activity in nonstimulated cells.
Furthermore, we examined the pH sensitivity of the
membrane-embedded oxytocin receptor and its dependence
on cholesterol. The ligand binding was highest at pH 7–9.
Clearly, in the presence of cholesterol, the oxytocin receptor
was significantly more stable at each of the pH values
tested. The observation that GPCRs are more susceptible
to denaturation at pH<7 as compared with pH>7 has been
recently reported for the h2 adrenergic receptor [26].
Does cholesterol acting as modulator and stabilizer of the
oxytocin receptor play a role for the regulation of oxytocin-
related physiological processes? Oxytocin is one of the most
potent uterotonic agents and is clinically used to induce
labor. Some reports suggest that particularly in reproductive
tissues, the cholesterol concentrations may be highly
dynamic. Using freeze-fracture cytochemistry with the cho-
lesterol-binding filipin, marked increases in cholesterol have
been found in rat uterine epithelial cells at the time of
blastocyst implantation [27]. At term, the cholesterol to
phospholipids ratio in human placental syncytiotrophoblast
membranes was found to be increased as compared with the
cholesterol/phospholipid ratio in early placentas [28]. More-
over, cholesterol-enriched caveolae structures are a conspic-
uous feature in the rat myometrium at term [29]. Plasma
membranes with lowered cholesterol content showed a
decreased capacity (Bmax) of binding sites and/or a
decreased affinity (Kd) of ligand–receptor binding. Interest-
ingly, Lopez et al. [30] reported that pregnancy in human
was associated with increases in density and affinity of
oxytocin receptors.
In conclusion, our results further support the hypothesis
that the molecular interaction of cholesterol and the oxy-
tocin receptor is a significant element of the steroid depend-
ence of the oxytocin receptor system as it has been
demonstrated in several physiological studies (reviewed in
Ref. [17]).
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